UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers

Radiation research, 2023-11, Vol.201 (1)

2023

Volltextzugriff (PDF)

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

The New England journal of medicine, 2017-01, Vol.376 (2), p.125-135

2017

Volltextzugriff (PDF)

Gene expression in neuroendocrine tumor liver metastases accurately distinguishes between pancreas and small bowel primary tumors

Journal of the American College of Surgeons, 2013-09, Vol.217 (3), p.S129-S129

2013

Volltextzugriff (PDF)

Somatic Alterations of CDKN1B Are Associated with Small Bowel Neuroendocrine Tumors

Journal of the American College of Surgeons, 2014-09, Vol.219 (3), p.S126-S127

2014

Volltextzugriff (PDF)

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

The Journal of nuclear medicine (1978), 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

Motor Neuron and Pancreas Homeobox 1 Mutations in Patients with Familial Neuroendocrine Tumors

Journal of the American College of Surgeons, 2018-10, Vol.227 (4), p.S85-S86

2018

Volltextzugriff (PDF)

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

The Journal of nuclear medicine (1978), 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

Distal Predilection of Small Bowel Neuroendocrine Tumors

Journal of the American College of Surgeons, 2016-10, Vol.223 (4), p.S46-S46

2016

Volltextzugriff (PDF)

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

The Journal of nuclear medicine (1978), 2017-07, Vol.58 (7), p.1054-1057

2017

Volltextzugriff (PDF)

Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Journal of the American College of Surgeons, 2015-10, Vol.221 (4), p.S60-S60

2015

Volltextzugriff (PDF)

Does liver tumor burden affect the therapeutic effect of 177Lu-Dotatate treatment? Analysis of Progression Free Survival, Safety and Quality of Life in NETTER-1 study

The Journal of nuclear medicine (1978), 2019-05, Vol.60

2019

Volltextzugriff (PDF)

Safety and efficacy of 68Ga-DOTATOC PET/CT in children and young adults

The Journal of nuclear medicine (1978), 2017-05, Vol.58, p.38

2017

Volltextzugriff (PDF)

Abstract 1368: RABL6A, a novel critical regulator of Akt-mTOR signaling in pancreatic neuroendocrine tumor cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1368-1368

2017

Volltextzugriff (PDF)

The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e14600-e14600

2012

Volltextzugriff (PDF)

The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.308-308

2012

Volltextzugriff (PDF)

Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.332-332

2012

Volltextzugriff (PDF)

Expression of vascular endothelial growth factor receptor (VEGF-R) and CD31 receptor (CD31-R) in high-grade neuroendocrine carcinoma of the uterine cervix (cNEC) and its association with prognosis

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15580-e15580

2012

Volltextzugriff (PDF)

Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e14620-e14620

2012

Volltextzugriff (PDF)

Phase I Trial of ^sup 90^Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

The Journal of nuclear medicine (1978), 2010-10, Vol.51 (10), p.1524

2010

Volltextzugriff (PDF)

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4085-4085

2012

Volltextzugriff (PDF)

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.312-312

2012

Volltextzugriff (PDF)

90 Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1652-1659

2010

Volltextzugriff (PDF)

sup 90^Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy

The Journal of nuclear medicine (1978), 2018-11, Vol.59 (11), p.1692

2018

Volltextzugriff (PDF)

Evaluating the clinical effectiveness of ^sup 90^Y-SMT 487 in patients with neuroendocrine tumors

The Journal of nuclear medicine (1978), 2003-10, Vol.44 (10), p.1556

2003

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

ThemaHumans

KollektionNUS Single-Journal Subscriptions

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(48)

Publikationsform

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Animals
(14)
Female
(9)
Dogs
(8)
Surgery
(8)
Male
(7)
Tumors
(7)
Biological And Medical Sciences
(5)
Gastroenterology & Hepatology
(5)
Gastric Inhibitory Polypeptide - Metabolism
(4)
Metastases
(4)
Neuroendocrine Tumors
(4)
Patients
(4)
Bone Marrow
(3)
Gastrointestinal Hormones - Metabolism
(3)
Glucose - Pharmacology
(3)
Medical Sciences
(3)
Positron Emission
(3)
Radiation Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Gene expression in neuroendocrine tumor liver metastases accurately distinguishes between pancreas and small bowel primary tumors

Somatic Alterations of CDKN1B Are Associated with Small Bowel Neuroendocrine Tumors

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Motor Neuron and Pancreas Homeobox 1 Mutations in Patients with Familial Neuroendocrine Tumors

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Distal Predilection of Small Bowel Neuroendocrine Tumors

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor

Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Does liver tumor burden affect the therapeutic effect of 177Lu-Dotatate treatment? Analysis of Progression Free Survival, Safety and Quality of Life in NETTER-1 study

Safety and efficacy of 68Ga-DOTATOC PET/CT in children and young adults

Abstract 1368: RABL6A, a novel critical regulator of Akt-mTOR signaling in pancreatic neuroendocrine tumor cells

The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs)

The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors

Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors

Expression of vascular endothelial growth factor receptor (VEGF-R) and CD31 receptor (CD31-R) in high-grade neuroendocrine carcinoma of the uterine cervix (cNEC) and its association with prognosis

Clinical outcomes and predictive value of chromogranin A (CgA) and pancreastatin (PcSt) in liver-directed therapies (LDTs) for well-differentiated metastatic neuroendocrine tumors

Phase I Trial of ^sup 90^Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study

Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study

90 Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

sup 90^Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy

Evaluating the clinical effectiveness of ^sup 90^Y-SMT 487 in patients with neuroendocrine tumors

Aktive Filter

Suchergebnisse filtern